The All Ordinaries Index (ASX: XAO) has soared 21.1% since plumbing 52-week lows in early April, but this ASX All Ords stock has left those gains wanting.
The surging stock in question is precious metals testing company Chrysos Corporation Ltd (ASX: C79).
On 9 April you could have picked up Chrysos shares at a one-year closing low of $3.49 each. (The All Ords hit its 52-week low on 7 April.)
On Monday, Chrysos shares closed changing hands for $8.77 apiece, putting them up 151.3% in only seven months. Or enough to turn a $10,000 investment into $25,129.
Boom!
But if you think the ship has already sailed on this surging ASX All Ords stock, you may want to have another think.
That's according to Jason Pohl, a partner at ECP Asset Management. The ECP Growth Companies fund owns Chrysos shares, and Pohl said he likes the company's outlook (courtesy of The Australian Financial Review).
Here's why.
Image source: Getty Images
ASX All Ords stock on the growth path
"Chrysos makes gold testing faster, cleaner and simpler," said Pohl.
And he's bullish on the ongoing potential of the ASX All Ords stock's metal testing machines.
According to Pohl:
Its PhotonAssay machines deliver highly accurate results in minutes rather than days and avoid cyanide and lead, removing a major safety and compliance burden for labs and miners. That speed matters where faster turnaround improves mine drill plans and operational grade control.
Citing the company's core strength, Pohl concluded:
With a distinctive value proposition, a lease-driven model that scales with use, and an exceptional chief executive, Dirk Treasure, the Chrysos team has the ingredients for steady, scalable compounding.
What's been happening with Chrysos shares?
Chrysos released its full year FY 2025 results on 26 August.
Highlights included revenue of $66.1 million, up 46% from FY 2024.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) of $16.1 million were up 80% from the prior year, with the company noting that economies of scale drove profitability.
Over the 12 months, the ASX All Ords stock deployed 11 PhotonAssay units, which brought the total to 40 units deployed.
And the company signed nine new leases in FY 2025, bringing total contracted PhotonAssay units to 59. That includes a Master Services Agreement and initial lease with the world's biggest gold miner, Newmont Corp (ASX: NEM).
Looking ahead, the ASX All Ords stock provided FY 2026 guidance for revenue in the range of $80 million to $90 million and EBITDA between $20 million and $27 million.
